Aspen Sells U.S. Arixtra Rights To Mylan For As Much As $300 Million
This article was originally published in PharmAsia News
South Africa's Aspen Pharmacare said it has signed a deal to sell U.S. rights to with Mylan's Ireland unit for its Arixtra (fondaparinux) for treating deep-vein thrombosis for as much as $300 million.
You may also be interested in...
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.